The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc ... organ transplants and other conditions and procedures, the FTC said. The report demonstrates how pharmacy benefit ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
The latest report accuses the PBMs — CVS Caremark ... bottom lines at the expense of the American health care system, according to the FTC. Specifically, the companies were able to generate ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Strawberry Hills Pharmacy owner Daniel Jones reacted Thursday to a recent Federal Trade Commission report which showed ...